Two immunotherapy drugs for colorectal cancer with residual disease
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs to see if they can stop colorectal cancer from returning after standard treatment. It is for people who still have cancer DNA in their blood after surgery and/or chemotherapy, which means they are at high risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have colorectal cancer (adenocarcinoma) that has been removed with surgery, and if you had stage 2 or 3 cancer, you've finished planned chemotherapy or radiation.
- After treatment, a special blood test (called ctDNA or minimal residual disease) must show that you have cancer DNA in your blood, which means there is a high risk of the cancer coming back.
- Your cancer must not be the type called MSI-high or dMMR.
- You must be in generally good health, with functioning kidneys, liver, and blood counts within certain limits.
- You must not have an active autoimmune disease or inflammatory bowel disease, and you must not have previously had this type of immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
Hear when a new Stage II Colorectal Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.